Inari Medical's Q3 2024 earnings call highlighted strong revenue growth, international expansion, and the upcoming PEERLESS study as significant positive developments. However, the company faced challenges with increased operating expenses and a net loss, suggesting a mixed but cautiously optimistic outlook.

Company Guidance -

Q3 2024

During the Inari Medical Q3 2024 earnings call, the company reported a record revenue of $153.4 million, reflecting a 21.4% increase year-over-year. The global VTE revenue was $145.3 million, up 19.7% from the previous year, and the emerging therapies segment saw a 64% rise to $8 million. International sales also surged by 76.4%, totaling $11.5 million, driven primarily by European adoption. Gross margins were noted at 87.1%, slightly down from the prior year's 88.5%, due to product mix and international expansion costs. Operating expenses increased to $147.1 million, with R&D costs at $29.4 million and SG&A expenses at $108.3 million. The company raised its full-year revenue guidance to $601.5 million - $604.5 million, projecting growth between 22% and 22.5%. Inari reaffirmed its goal to achieve sustained operating profitability by the first half of 2025, anticipating breakeven GAAP operating income in Q4 of 2024.

Record Revenue and Growth

In Q3, Inari Medical achieved record revenue of $153.4 million, representing a 21% year-over-year growth. The company raised its full-year revenue guidance and expects sustained operating profitability in the first half of 2025.

International and Emerging Therapies Expansion

Inari's international revenue reached $11.5 million, a 76.4% increase from the prior year, primarily driven by Europe. Emerging Therapies revenue was over $8 million, up 64% year-over-year.

PEERLESS Study and Market Opportunities

The upcoming PEERLESS study presentation is expected to enhance the adoption of FlowTriever. Inari sees a $150 million opportunity to convert catheter-directed thrombolytic procedures to mechanical thrombectomy.

Strong Gross Margins

Inari maintained a best-in-class gross margin of 87.1% for Q3 2024, showing sequential improvement over the previous quarter.

Advancements in New Products

The company launched its next-gen Artix system after receiving 510(k) clearance and commenced a limited market release, addressing a $600 million U.S. TAM.

Inari Medical (NARI) Earnings, Revenues Date & History

The upcoming earnings date is based on a company’s previous reporting, and may be updated when the actual date is announced

Daily Earnings Calendar >

NARI Earnings History

Report Date	Fiscal Quarter	Forecast / EPS	Last Year's EPS	EPS YoY Change	Slides	Play Transcript
Mar 04, 2025	2024 (Q4)	-0.11 / -	-0.08	―	―	―
Oct 28, 2024	2024 (Q3)	-0.12 / -0.08	0.05	-268.00% (-0.13)
Jul 30, 2024	2024 (Q2)	-0.19 / -0.38	0.04	-1055.00% (-0.42)
Apr 30, 2024	2024 (Q1)	-0.16 / -0.22	-0.04	-452.50% (-0.18)
Feb 28, 2024	2023 (Q4)	<0.01 / -0.08	-0.11	27.27% (+0.03)
Nov 01, 2023	2023 (Q3)	0.01 / 0.05	-0.19	126.32% (+0.24)
Aug 02, 2023	2023 (Q2)	-0.13 / 0.04	-0.19	121.05% (+0.23)	―
May 03, 2023	2023 (Q1)	-0.23 / -0.04	-0.06	33.33% (+0.02)	―
Feb 27, 2023	2022 (Q4)	-0.17 / -0.11	0.02	-650.00% (-0.13)
Nov 02, 2022	2022 (Q3)	-0.25 / -0.19	-0.06	-216.67% (-0.13)

The table shows recent earnings report dates and whether the forecast was beat or missed. See the change in forecast and EPS from the previous year.

Beat

Missed

NARI Earnings-Related Price Changes

Report Date	Price 1 Day Before	Price 1 Day After	Percentage Change
Oct 28, 2024	$42.56	$49.18	+15.55%
Jul 30, 2024	$52.11	$46.56	-10.65%
Apr 30, 2024	$37.34	$41.60	+11.41%
Feb 28, 2024	$58.26	$46.12	-20.84%

Earnings announcements can affect a stock’s price. This table shows the stock's price the day before and the day after recent earnings reports, including the percentage change.

FAQ

When does Inari Medical, Inc. (NARI) report earnings?

Inari Medical, Inc. (NARI) is schdueled to report earning on Mar 04, 2025, After Close (Confirmed).

What is Inari Medical, Inc. (NARI) earnings time?

Inari Medical, Inc. (NARI) earnings time is at Mar 04, 2025, After Close (Confirmed).

Where can I see when companies are reporting earnings?

You can see which companies are reporting today on our designated earnings calendar.

What companies are reporting earnings today?

You can see a list of the companies which are reporting today on TipRanks earnings calendar.

What is NARI EPS forecast?

NARI EPS forecast for the fiscal quarter 2024 (Q4) is -0.11.

Become an Expert with TipRanks Premium

What am I Missing?

Make informed decisions based on Top Analysts' activity

Know what industry insiders are buying

Get actionable alerts from top Wall Street Analysts

Find out before anyone else which stock is going to shoot up

Get powerful stock screeners & detailed portfolio analysis

Subscribe Now See Plans & Pricing